Business Description
Septerna Inc
NAICS : 541714
SIC : 2834
ISIN : US81734D1046
Total Employee Number:
130Description
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 15.05 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.35 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 5.69 | |||||
Beneish M-Score | 60.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -8.4 | |||||
3-Year EPS without NRI Growth Rate | 0.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -36.82 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.23 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 71.54 | |||||
9-Day RSI | 67.05 | |||||
14-Day RSI | 63.01 | |||||
3-1 Month Momentum % | 49.42 | |||||
6-1 Month Momentum % | 41.01 | |||||
12-1 Month Momentum % | 206.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.71 | |||||
Quick Ratio | 4.71 | |||||
Cash Ratio | 4.44 | |||||
Days Sales Outstanding | 30.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.2 | |||||
Shareholder Yield % | -0.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -94.37 | |||||
Net Margin % | -49.88 | |||||
EBITDA Margin % | -92.12 | |||||
FCF Margin % | 147.99 | |||||
OCF Margin % | 149.33 | |||||
ROE % | -9.35 | |||||
ROA % | -6.87 | |||||
ROIC % | -38.53 | |||||
3-Year ROIIC % | -21.21 | |||||
ROC (Joel Greenblatt) % | -256.48 | |||||
ROCE % | -14.47 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 46.02 | |||||
PS Ratio | 24.14 | |||||
PB Ratio | 4.61 | |||||
Price-to-Tangible-Book | 4.61 | |||||
Price-to-Free-Cash-Flow | 16.76 | |||||
Price-to-Operating-Cash-Flow | 16.62 | |||||
EV-to-EBIT | -20.91 | |||||
EV-to-Forward-EBIT | 10.33 | |||||
EV-to-EBITDA | -21.42 | |||||
EV-to-Revenue | 19.74 | |||||
EV-to-Forward-Revenue | 23.96 | |||||
EV-to-FCF | 13.34 | |||||
| Price-to-Net-Current-Asset-Value | 9.86 | |||||
| Price-to-Net-Cash | 11.16 | |||||
Earnings Yield (Greenblatt) % | -4.78 | |||||
FCF Yield % | 6.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SEPN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Septerna Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 72.255 | ||
| EPS (TTM) ($) | -0.81 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 77.15 | ||
| 14-Day RSI | 63.01 | ||
| 14-Day ATR ($) | 2.299769 | ||
| 20-Day SMA ($) | 34.8185 | ||
| 12-1 Month Momentum % | 206.24 | ||
| 52-Week Range ($) | 10.6161 - 40.65 | ||
| Shares Outstanding (Mil) | 45.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Septerna Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Septerna Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 94 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 3 days | ||
| General meeting for 2026 | 2026-06-26 14:00 | 34.54 (-5.01%) | ||
| Bank of America Securities Health Care Conference | 2026-05-12 17:00 | 23.57 (-1.26%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 23.87 (-0.46%) | ||
| Annual report for 2026 | 2026-03-09 | 28.78 (+6.40%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 28.78 (+6.40%) | ||
| the TD Cowen 46(th) Annual Health Care Conference | 2026-03-03 15:10 | 28.64 (+1.89%) | ||
| https://ccdbwebprod.dcc8fc7.eas.morningstar.com/CCDB/Files/648297295.html | 2026-03-02 08:00 | 29.02 (-2.58%) | ||
| 44(th) Annual J.P. Morgan Healthcare Conference | 2026-01-13 15:45 | 24.88 (-2.39%) |
Show
Entries
Septerna Inc Frequently Asked Questions
What is Septerna Inc(SEPN)'s stock price today?
The current price of SEPN is $38.83. The 52 week high of SEPN is $40.65 and 52 week low is $10.62.
When is next earnings date of Septerna Inc(SEPN)?
The next earnings date of Septerna Inc(SEPN) is 2026-08-11 Est..
Does Septerna Inc(SEPN) pay dividends? If so, how much?
Septerna Inc(SEPN) does not pay dividend.
Guru Commentaries on NAS:SEPN
No articles.
Press Release
Articles on Septerna Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers